Xcell Biosciences

Xcell Biosciences, based at 455 Mission Bay Blvd S, San Francisco, CA 94158, focuses on developing advanced technologies for cell therapy research and treatment. The company offers the AVATAR System, an incubator tailored for the cultivation of primary human cells, allowing precise control over oxygen and pressure levels to optimize culture conditions for specific cell types. Additionally, Xcell Biosciences provides the AVATAR Foundry, an automated, closed system for producing autologous cell therapies, which is currently in beta testing. The AVATAR AI platform leverages advanced machine learning algorithms to predict IC50 values and dose response curves in real-time, facilitating rapid and accurate potency assays for cell therapy products. The company has a longstanding partnership with Labcorp, which includes new financing and beta access to clinical manufacturing instruments. Its investors include Casdin Capital, Viking Global Investors, Dynamk Capital, Labcorp, HBM Healthcare, Lightspeed Capital, and Illumina. Xcell Biosciences aims to enhance the metabolic fitness of cell therapies and offers products designed to overcome the solid tumor microenvironment. The company supports preclinical, translational, and clinical stages of cell therapy research and provides a range of publications, posters, white papers, and application notes on their website. Xcell Biosciences is dedicated to developing novel immunotherapy-focused technologies to combat cancer and offers a beta program for the AVATAR Foundry and AVATAR AI. The company also provides job opportunities and encourages applications through their careers page.